ArticleMMWR. Morbidity and mortality weekly report2024
Surveillance for Lyme Disease After Implementation of a Revised Case Definition - United States, 2022.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Mortality dynamics of West Nile virus and Lyme disease in the United States: Temporal, spatial, and socioeconomic dimensions (2003-2021).Environmental epidemiology (Philadelphia, Pa.) · 2026Article
- The ecology of Lyme disease: Long-term data, surprises, and a synthesis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Findings From Electronic Medical Record Review of 2500 Patients Identified With Lyme Disease Diagnoses, Test Orders, and Antibiotic Orders in the SubLyme Network.Open forum infectious diseases · 2026Article
- Bactofilins are essential spatial organizers of peptidoglycan insertion in the Lyme disease spirocheteJournal of bacteriology · 2026Article
- Protective efficacy of mutant strains ofInfection and immunity · 2026Article
- Evaluation of EcoCRM, virus-like particles, and mRNA as vaccine platforms against Borrelia burgdorferi.Vaccine · 2026Article
- Epidemiology of Lyme disease, a growing tick-borne disease of concern, in Japan from May 2013 to March 2024: a descriptive study.IJID regions · 2026Article
- Efficacy of Purified Borrelial Lipoproteins (PBL) as an oral formulation in reducing transmission of Lyme spirochetes from reservoir hosts tobioRxiv : the preprint server for biology · 2026Article
- Imported Pediatric Lyme Disease in Singapore-A Case Series.Pathogens (Basel, Switzerland) · 2026Article
- Guillain-Barré Polyradiculoneuritis Developed in the Context of Lyme Neuroborreliosis in a 13-Year-Old Girl: A Case Report.Children (Basel, Switzerland) · 2026Article
- Lyme borreliosis.Nature reviews. Disease primers · 2026Review
- Pathogens of the Human Central Nervous System- the Major Bacterial Pathogens.Molecular neurobiology · 2026Review
- Article
- Changing case definition: An analysis of its impact on Lyme disease surveillance in Nova Scotia.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- DNA Binding by BosR Controls RpoS-Dependent and -Independent Gene Expression in Borrelia burgdorferi.Molecular microbiology · 2026Article
- Lyme Disease and Health Care Costs.JAMA network open · 2026Article
- Perspectives on Lyme disease among persons of color in the United States: Qualitative research findings.Qualitative research in medicine & healthcare · 2026Article
- Retrospective Case Series of Ocular Lyme Disease, 1988-2025.Emerging infectious diseases · 2026Review
- Interlaboratory Concordance of a Multiplex ELISA for Lyme and Lyme-like Illness Using Australian Samples and Commercial Reference Panels: A Proof-of-Concept Study.Pathogens (Basel, Switzerland) · 2025Article
- Variables for habitat and vertebrate hosts of Ixodes scapularis are the best ecological predictors of the spatial spread of Lyme disease in the United States (2010-2019).Parasites & vectors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lyme disease, a tickborne zoonosis caused by certain species of Borrelia spirochetes, is the most common vectorborne disease in the United States. Approximately 90% of all cases are reported from 15 high-incidence jurisdictions in the Northeast, mid-Atlantic, and upper-Midwest regions. After the implementation of a revised surveillance case definition in 2022, high-incidence jurisdictions report cases based on laboratory evidence alone, without need for additional clinical information. In 2022, 62,551 Lyme disease cases were reported to CDC, 1.7 times the annual average of 37,118 cases reported during 2017-2019. Annual incidence increased most in older age groups, with incidence among adults aged ≥65 years approximately double that during 2017-2019. The sharp increase in reported Lyme disease cases in 2022 likely reflects changes in surveillance methods rather than change in disease risk. Although these changes improve standardization of surveillance across jurisdictions, they preclude detailed comparison with historical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.